“This is a slightly different approach [than] we have taken before given the high demand there is. We are continuing to roll it out,” Camilla Sylvest, executive vice president of commercial strategy and corporate affairs, said in a call with investors. “You can say we take a responsible approach and an approach that considers the high uptake on the demand so that we can ensure patient continuity.”
The company told CNBC it is working to increase Wegovy supply in the short- and long-term but will continue to ration lower-dose strengths.
On July 20, the FDA posted an update on the Wegovy shortage and listed the 0.25 milligram / 0.5 milliliter, 0.5 milligram / 0.5 milliliter and 1 milligram / 0.5 milliliter solutions as being in limited availability through September.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
